Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 14

1.

Gossypol induces apoptosis by activating p53 in prostate cancer cells and prostate tumor-initiating cells.

Volate SR, Kawasaki BT, Hurt EM, Milner JA, Kim YS, White J, Farrar WL.

Mol Cancer Ther. 2010 Feb;9(2):461-70. doi: 10.1158/1535-7163.MCT-09-0507. Epub 2010 Feb 2.

2.

Effects of the sesquiterpene lactone parthenolide on prostate tumor-initiating cells: An integrated molecular profiling approach.

Kawasaki BT, Hurt EM, Kalathur M, Duhagon MA, Milner JA, Kim YS, Farrar WL.

Prostate. 2009 Jun 1;69(8):827-37. doi: 10.1002/pros.20931.

3.

Targeting cancer stem cells with phytochemicals.

Kawasaki BT, Hurt EM, Mistree T, Farrar WL.

Mol Interv. 2008 Aug;8(4):174-84. doi: 10.1124/mi.8.4.9. Review.

PMID:
18829843
4.

Activation of signal transducer and activator of transcription 3 through a phosphomimetic serine 727 promotes prostate tumorigenesis independent of tyrosine 705 phosphorylation.

Qin HR, Kim HJ, Kim JY, Hurt EM, Klarmann GJ, Kawasaki BT, Duhagon Serrat MA, Farrar WL.

Cancer Res. 2008 Oct 1;68(19):7736-41. doi: 10.1158/0008-5472.CAN-08-1125.

5.

Cancer stem cells, CD200 and immunoevasion.

Kawasaki BT, Farrar WL.

Trends Immunol. 2008 Oct;29(10):464-8. doi: 10.1016/j.it.2008.07.005. Epub 2008 Sep 3.

PMID:
18775673
6.

CD44+ CD24(-) prostate cells are early cancer progenitor/stem cells that provide a model for patients with poor prognosis.

Hurt EM, Kawasaki BT, Klarmann GJ, Thomas SB, Farrar WL.

Br J Cancer. 2008 Feb 26;98(4):756-65. doi: 10.1038/sj.bjc.6604242. Epub 2008 Feb 12.

7.

Co-expression of the toleragenic glycoprotein, CD200, with markers for cancer stem cells.

Kawasaki BT, Mistree T, Hurt EM, Kalathur M, Farrar WL.

Biochem Biophys Res Commun. 2007 Dec 28;364(4):778-82. Epub 2007 Oct 25.

8.

TGFBR3 loss and consequences in prostate cancer.

Sharifi N, Hurt EM, Kawasaki BT, Farrar WL.

Prostate. 2007 Feb 15;67(3):301-11.

PMID:
17192875
9.

Stem cells in prostate cancer: resolving the castrate-resistant conundrum and implications for hormonal therapy.

Sharifi N, Kawasaki BT, Hurt EM, Farrar WL.

Cancer Biol Ther. 2006 Aug;5(8):901-6. Epub 2006 Aug 28. Review.

PMID:
16855379
10.
11.

Molecular cloning of TRPC3a, an N-terminally extended, store-operated variant of the human C3 transient receptor potential channel.

Yildirim E, Kawasaki BT, Birnbaumer L.

Proc Natl Acad Sci U S A. 2005 Mar 1;102(9):3307-11. Epub 2005 Feb 22.

12.

Obligatory role of Src kinase in the signaling mechanism for TRPC3 cation channels.

Vazquez G, Wedel BJ, Kawasaki BT, Bird GS, Putney JW Jr.

J Biol Chem. 2004 Sep 24;279(39):40521-8. Epub 2004 Jul 22.

13.
14.

Distinct distributions of alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionate (AMPA) receptor subunits and a related 53,000 M(R) antigen (GR53) in brain tissue.

Bahr BA, Hoffman KB, Kessler M, Hennegriff M, Park GY, Yamamoto RS, Kawasaki BT, Vanderklish PW, Hall RA, Lynch G.

Neuroscience. 1996 Oct;74(3):707-21.

PMID:
8884767

Supplemental Content

Loading ...
Support Center